Anavex Life Sciences Corp. (AVXL)
NASDAQ: AVXL · Real-Time Price · USD
8.52
+0.05 (0.53%)
Nov 21, 2024, 10:59 AM EST - Market open
Anavex Life Sciences Employees
Anavex Life Sciences had 40 employees as of September 30, 2023. The number of employees increased by 2 or 5.26% compared to the previous year.
Employees
40
Change (1Y)
2
Growth (1Y)
5.26%
Revenue / Employee
n/a
Profits / Employee
-$1,038,200
Market Cap
722.46M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| agilon health | 1,117 |
| Definitive Healthcare | 950 |
| Phathom Pharmaceuticals | 452 |
| Ironwood Pharmaceuticals | 267 |
| Entrada Therapeutics | 159 |
| IRADIMED CORPORATION | 148 |
| Stoke Therapeutics | 110 |
| ORIC Pharmaceuticals | 100 |
AVXL News
- 15 days ago - Anavex Life Sciences: Weighing The Pros And Cons Of A Possible EU Approval Scenario - Seeking Alpha
- 21 days ago - Anavex's Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer's Trial: Data Presented at CTAD Conference 2024 - GlobeNewsWire
- 5 weeks ago - Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia - GlobeNewsWire
- 2 months ago - Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024 - GlobeNewsWire
- 3 months ago - Anavex Life Sciences Corp. (AVXL) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update - GlobeNewsWire
- 4 months ago - Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024 - GlobeNewsWire
- 4 months ago - Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference - GlobeNewsWire